Stash This Growth Stock in Your TFSA Forever

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) stock holds huge promise going forward on the back of its flagship products ZW25 and ZW49.

| More on:

Zymeworks (TSX:ZYME)(NYSE:ZYME) is a Vancouver-based clinical-stage biopharmaceutical company. Shares of Zymeworks fell 5.4% on January 3. The stock is up 87% year over year.

In previous articles, I have discussed why Zymeworks will remain on my radar heading into the next decade. The company has shown early promise with its ZW25 flagship product, currently in clinical trials, and just filed an Investigational New Drug (IND) Application for ZW49. The development of the former has shown how effective the company has been in combining its therapeutic platforms. Zymeworks projects that it will be able to launch clinical trails for ZW49 this year.

The broad potential of the breast cancer therapeutics market is one of several reasons to keep Zymeworks in your portfolio. The North American breast cancer therapeutics market accounts for over 35% of the total global market, according to a report from Transparency Market Research. Demand for therapeutics is rising primarily due to the increased prevalence of breast cancer among women worldwide. The risk of developing cancers rises with age, so demographics in the developed world are also playing into the growth of this market.

Zymeworks’s lead drug ZW25 has produced promising phase one data and aims to compete with drugs like Herceptin and Perjeta if it is able to move to market. Roche Holding AG’s blockbuster breast cancer treatment drug Herceptin generated sales of $7.18 billion in 2017. This has been the main contributor to Roche’s profits — a company boasting an over $200 billion market cap. Perjeta, also sold by Roche, had reported $2 billion in sales in the first nine months of 2018 — up 24% from the prior year.

Zymeworks has already entered partnership and collaboration deals with eight pharmaceutical companies. Its most consequential recent partnership was with BeiGene. Zymeworks gave BeiGene exclusive development and commercial rights to ZW25 and ZW49 in Asia, excluding Japan, and Oceania. This includes $40 million up front, and Zymeworks is eligible to receive development and commercial milestone payments plus royalties on product sales.

Shares of Zymeworks have dropped 2.9% over the past three months. The stock reached an all-time high of $30.36 in early June before sharply correcting. Its performance has ranged in the $15-20 range since then. Zymeworks stock last boasted an RSI of 56 as of close on January 3. This indicates that the stock is neither oversold nor overbought in early January.

In the third quarter, Zymeworks reported revenue of $2.1 million compared to $0.1 million in the prior year. Research and development expenditures rose to $14.1 million compared to $11.5 million in Q3 2017. Investors should expect its Q4 results in early March.

Zymeworks’s product development holds huge promise, but the company is still working through clinical trials on ZW25 and ZW49. As we have discussed, if it moves into market, these products have the potential to rival peers that have charted billions in annual sales. This is reason enough to monitor Zymeworks and consider a speculative buy today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Investing

Tired or stressed businessman sitting on the walkway in panic digital stock market financial background
Stocks for Beginners

Buying These 2 Stocks Is a Good Way to Hedge Against a Falling Market

Investors looking to hedge against a stock downturn should consider these two stocks as viable long-term picks.

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

How I’d Invest $1000 in February to Make Easy Passive Income

Looking to earn some extra passive income in February but don't have much cash? Build an easy portfolio with these…

Read more »

The sun sets behind a high voltage telecom tower.
Energy Stocks

2 Utilities Stocks With Sought-After Stability

Here's why Fortis and Hydro One are two top utilities stocks long-term investors may want to consider right now.

Read more »

clock time
Tech Stocks

3 Top ‘Future’ Stocks to Hold for the Rest of This Decade

Canadian growth stocks like Constellation Software are starting to look appealing.

Read more »

Coworkers standing near a wall
Investing

Is Restaurant Brands International Stock Worth Buying in February 2023?

After an impressive rally, does restaurant stock QSR have more room to grow, or is it already fairly valued?

Read more »

financial freedom sign
Investing

Millionaire by 40: Top 4 Ways to Hit Your 1st Million

Canadians who want to hit the millionaire milestone by the time they hit 40 may want to target growth stocks…

Read more »

Dollar symbol and Canadian flag on keyboard
Stocks for Beginners

2 Canadian Stocks I’ll Be Buying Hand Over Fist in 2023

There are some great Canadian stocks on sale right now. Here's a duo of companies I'm buying that you may…

Read more »

Women's fashion boutique Aritzia is a top stock to buy in September 2022.
Stocks for Beginners

Has ATZ Stock Bottomed Out?

Has ATZ stock finally bottomed out after losing nearly 10% of its value in 2022? Let’s find out.

Read more »